{"transactions":[{"id":917305,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-05T21:12:45.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":230000,"derivative":{"exercise_price":2.3,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":230000},"source":{"system":"sec-edgar","filing":"0001824632-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000182463226000002/primarydocument.xml","form_type":"4"}},{"id":1281398,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-05T21:32:45.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":175000,"derivative":{"exercise_price":1.11,"expiration_date":"2035-02-04","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001562180-25-000958","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218025000958/primarydocument.xml","form_type":"4"}},{"id":1602265,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-04T23:07:15.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":4.59,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001562180-24-002137","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218024002137/primarydocument.xml","form_type":"4"}},{"id":2024321,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-09T21:08:51.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":135000,"derivative":{"exercise_price":7.2,"expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001562180-23-001170","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000156218023001170/primarydocument.xml","form_type":"4"}},{"id":2387340,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-18T00:12:14.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":10.58,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-011038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919122011038/doc4.xml","form_type":"4"}},{"id":2586179,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-27","kind":"exercise","acquired":false,"shares":6014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":27018,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":6014},"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586178,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-26","kind":"exercise","acquired":false,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":33032,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586177,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-27","kind":"sale","acquired":false,"shares":607,"price":37.0761,"value":22505.1927,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586176,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-27","kind":"sale","acquired":false,"shares":2707,"price":36.234,"value":98085.438,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":173527,"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586175,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-27","kind":"sale","acquired":false,"shares":2700,"price":35.3247,"value":95376.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":176234,"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586174,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-27","kind":"exercise","acquired":true,"shares":6014,"price":1.43,"value":8600.02,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":178934,"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586173,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-26","kind":"sale","acquired":false,"shares":1700,"price":35.1879,"value":59819.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2586172,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-30T21:16:37.000Z","date":"2021-08-26","kind":"exercise","acquired":true,"shares":1700,"price":1.43,"value":2431.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":174620,"source":{"system":"sec-edgar","filing":"0001209191-21-053867","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121053867/doc4.xml","form_type":"4"}},{"id":2599224,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-17T20:44:45.000Z","date":"2021-08-13","kind":"exercise","acquired":false,"shares":1728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":34732,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":1728},"source":{"system":"sec-edgar","filing":"0001209191-21-051885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121051885/doc4.xml","form_type":"4"}},{"id":2599223,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-08-17T20:44:45.000Z","date":"2021-08-13","kind":"exercise","acquired":false,"shares":558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested as to 25% of the total shares monthly beginning on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":42672,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":558},"source":{"system":"sec-edgar","filing":"0001209191-21-051885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121051885/doc4.xml","form_type":"4"}},{"id":2599222,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-17T20:44:45.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":2286,"price":35.0662,"value":80161.3332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-051885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121051885/doc4.xml","form_type":"4"}},{"id":2599221,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-17T20:44:45.000Z","date":"2021-08-13","kind":"exercise","acquired":true,"shares":1728,"price":1.43,"value":2471.04,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":175206,"source":{"system":"sec-edgar","filing":"0001209191-21-051885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121051885/doc4.xml","form_type":"4"}},{"id":2599220,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-17T20:44:45.000Z","date":"2021-08-13","kind":"exercise","acquired":true,"shares":558,"price":1.89,"value":1054.62,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":173478,"source":{"system":"sec-edgar","filing":"0001209191-21-051885","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121051885/doc4.xml","form_type":"4"}},{"id":2621882,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-29T23:27:26.000Z","date":"2021-07-27","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":36460,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-048688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121048688/doc4.xml","form_type":"4"}},{"id":2621881,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-07-29T23:27:26.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":680,"price":36.0882,"value":24539.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-048688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121048688/doc4.xml","form_type":"4"}},{"id":2621880,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-07-29T23:27:26.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":19320,"price":35.4472,"value":684839.904,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":173600,"source":{"system":"sec-edgar","filing":"0001209191-21-048688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121048688/doc4.xml","form_type":"4"}},{"id":2621879,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-07-29T23:27:26.000Z","date":"2021-07-27","kind":"exercise","acquired":true,"shares":20000,"price":1.43,"value":28600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":192920,"source":{"system":"sec-edgar","filing":"0001209191-21-048688","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121048688/doc4.xml","form_type":"4"}},{"id":2626903,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-22T22:17:29.000Z","date":"2021-07-20","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":95000,"derivative":{"exercise_price":31.23,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-047847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121047847/doc4.xml","form_type":"4"}},{"id":2717998,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-05-11T22:46:13.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":56460,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-031847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121031847/doc4.xml","form_type":"4"}},{"id":2717997,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-11T22:46:13.000Z","date":"2021-05-07","kind":"sale","acquired":false,"shares":200,"price":41.85,"value":8370.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-031847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121031847/doc4.xml","form_type":"4"}},{"id":2717996,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-11T22:46:13.000Z","date":"2021-05-07","kind":"sale","acquired":false,"shares":5836,"price":41.1395,"value":240090.122,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.67 to $41.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":173120,"source":{"system":"sec-edgar","filing":"0001209191-21-031847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121031847/doc4.xml","form_type":"4"}},{"id":2717995,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-11T22:46:13.000Z","date":"2021-05-07","kind":"sale","acquired":false,"shares":3964,"price":40.2957,"value":159732.1548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.64 to $40.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":178956,"source":{"system":"sec-edgar","filing":"0001209191-21-031847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121031847/doc4.xml","form_type":"4"}},{"id":2717994,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-11T22:46:13.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":10000,"price":1.43,"value":14300.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":182920,"source":{"system":"sec-edgar","filing":"0001209191-21-031847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121031847/doc4.xml","form_type":"4"}},{"id":2748227,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-15T23:14:17.000Z","date":"2021-04-08","kind":"exercise","acquired":false,"shares":4630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":66460,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":4630},"source":{"system":"sec-edgar","filing":"0001209191-21-026875","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026875/doc4.xml","form_type":"4"}},{"id":2748226,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-15T23:14:17.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":1669,"price":39.5688,"value":66040.3272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.39 to $40.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-026875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026875/doc4.xml","form_type":"4"}},{"id":2748225,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-15T23:14:17.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":669,"price":38.9726,"value":26072.6694,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.38 to $39.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":174589,"source":{"system":"sec-edgar","filing":"0001209191-21-026875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026875/doc4.xml","form_type":"4"}},{"id":2748224,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-15T23:14:17.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":875,"price":37.7182,"value":33003.425,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.38 to $38.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":175258,"source":{"system":"sec-edgar","filing":"0001209191-21-026875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026875/doc4.xml","form_type":"4"}},{"id":2748223,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-15T23:14:17.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":1417,"price":36.9707,"value":52387.4819,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.37 to $37.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":176133,"source":{"system":"sec-edgar","filing":"0001209191-21-026875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026875/doc4.xml","form_type":"4"}},{"id":2748222,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-15T23:14:17.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":4630,"price":1.43,"value":6620.9,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":177550,"source":{"system":"sec-edgar","filing":"0001209191-21-026875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026875/doc4.xml","form_type":"4"}},{"id":2751811,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-09T21:55:05.000Z","date":"2021-04-07","kind":"exercise","acquired":false,"shares":15370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":71090,"derivative":{"exercise_price":1.43,"expiration_date":"2028-11-12","underlying":"Common Stock","underlying_shares":15370},"source":{"system":"sec-edgar","filing":"0001209191-21-026294","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026294/doc4.xml","form_type":"4"}},{"id":2751810,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-09T21:55:05.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":200,"price":40.3,"value":8060.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":172920,"source":{"system":"sec-edgar","filing":"0001209191-21-026294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026294/doc4.xml","form_type":"4"}},{"id":2751809,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-09T21:55:05.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":6881,"price":39.6278,"value":272678.8918,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":173120,"source":{"system":"sec-edgar","filing":"0001209191-21-026294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026294/doc4.xml","form_type":"4"}},{"id":2751808,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-09T21:55:05.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":8289,"price":39.0162,"value":323405.2818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":180001,"source":{"system":"sec-edgar","filing":"0001209191-21-026294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026294/doc4.xml","form_type":"4"}},{"id":2751807,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":67555,"kind":"person","name":"Scherle Peggy","position":1,"cik":"0001824632","reported_name":"Scherle Peggy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-09T21:55:05.000Z","date":"2021-04-07","kind":"grant","acquired":true,"shares":15370,"price":1.43,"value":21979.1,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met."}],"balance_after":188290,"source":{"system":"sec-edgar","filing":"0001209191-21-026294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026294/doc4.xml","form_type":"4"}}]}